Aegerion’s management team, board and scientific advisors are leaders in their respective fields focused on research, development, commercialization and treatment of debilitating and fatal orphan diseases. We are all committed to delivering our products to people afflicted with rare and often fatal diseases who need them.

Marc Beer

Chief Executive Officer

Marc Beer is the Chief Executive Officer of Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR). Aegerion is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. Marc took the company public in October 2010. The Company’s first marketed product, JUXTAPID® (lomitapide) was approved by the U.S. Food and Drug Administration in December 2012... 
Read more & view related media



Will Andrews, MD, FACP 

Senior Vice President, Business Development

William “Will” Andrews was appointed Senior Vice President of Business Development in May 2014. Dr. Andrews assumed the business development role after having spent two years as Vice President of Medical Affairs for Aegerion, starting and building the Medical Affairs function and overseeing medical affairs activities for the launch of JUXTAPID® in the United States, Canada, Latin America, and Asia. Prior to joining Aegerion in 2012, Dr. Andrews held Medical Affairs leadership roles with Santhera Pharmaceuticals and Sepracor. Before that, he was Medical Director at ClinQuest, where he worked on the Clinical Development of multiple innovative therapies and programs. Prior to joining the biopharmaceutical industry over 15 years ago, Dr. Andrews practiced Internal Medicine in Boston at Harvard Vanguard Medical Associates and Brigham and Women’s Hospital. He has also served as Clinical Instructor of Internal Medicine at Harvard Medical School and Attending Physician of Internal Medicine at Brigham and Women’s Hospital. Dr. Andrews received his Doctor of Medicine degree from Yale University School of Medicine, and his Bachelor of Arts degree in Biology from Harvard University.

Martha Carter

Chief Regulatory Officer

Martha Carter was appointed Chief Regulatory Officer of Aegerion in February 2011, bringing over 30 years of regulatory affairs experience in prescription and over-the-counter drugs, biologics, biotechnology products, and medical devices. Prior to joining Aegerion, Martha was Senior Vice President and Chief Regulatory Officer at Proteon Therapeutics, Inc. where she was responsible for the company's worldwide regulatory and quality functions. Prior to this role, she was Senior Vice President, Regulatory Affairs, for Trine Pharmaceuticals. Prior to that, Martha was Vice President, Regulatory Affairs for GelTex Pharmaceuticals, Inc. In this role, she led the company's regulatory and quality control functions for both commercial and investigational drug products. Martha is a Fellow of the Regulatory Affairs Professionals Society, and is a past President and Chairman of the Board. She is also a former member of the Editorial Advisory Board for Applied Clinical Trials and BioPharm. Martha holds a B.A. in Biology from Northeastern University.

Anne Marie Cook

Senior Vice President, General Counsel and Secretary

Anne Marie Cook was appointed Senior Vice President, General Counsel and Secretary in December 2011. Ms. Cook was most recently a partner with Boston-based law firm Choate Hall & Stewart LLP (Choate). There she represented life science companies in structuring and negotiating strategic transactions such as joint ventures, collaborations, mergers and acquisitions and intellectual property licenses. She also provided general legal support in connection with the research, development and commercialization of pharmaceutical products. Prior to joining Choate, Ms. Cook was Senior Vice President, Business & Corporate Development, General Counsel at ViaCell, Inc. Prior to that, she was Vice President, Chief Corporate Counsel, at Biogen Idec Inc.

Craig Fraser

Chief Operating Officer

Craig Fraser was appointed Chief Operating Officer in July 2014. Prior to that, he was President, U.S. Commercial and Global Manufacturing and Supply Chain for Aegerion since September 2012.  Before joining Aegerion, Mr. Fraser was Vice President, Global Disease Areas at Pfizer Inc. responsible for the commercial development and global marketing for the Specialty Cardiovascular, Anti-Bacterial, Anti-Fungal, Gastrointestinal and Anti-Viral disease areas, where he managed a portfolio of six products totaling over three billion dollars in revenue and multiple new products in development. He was charged with establishing the company's future specialty cardiovascular business including commercial inputs for the rare disease lipid market.   Prior to Pfizer, Mr. Fraser was Vice President and Global Business Manager at Wyeth, where he led the institutional/infectious disease business. Before that, Mr. Fraser held several commercial positions at Johnson & Johnson, most recently as Vice President, Commercial Operations and Oncology Sales and Marketing. Previously, he was Gastroenterology Franchise lead as well as National Sales Director of the Immunology and Cardiovascular business units at Centocor, a start-up biotech and diagnostic company focused on monoclonal antibody-based technology.

Mark Sumeray, MD, MS, FRCS

Chief Medical Officer

Dr. Sumeray brings development, regulatory and medical affairs experience with cardiovascular drugs such as Plavix®, apixaban, Avapro®/Avalide®, and Angiomax® to Aegerion. Dr. Sumeray was most recently Vice President Cardiovascular/Metabolics U.S. Medical, at Bristol-Myers Squibb. In this role, he was responsible for U.S. medical strategy for the CV and metabolics medical strategy teams, including implementation across the medical affairs function working collaboratively with marketing, sales, global clinical research and health outcomes. Prior to this role, Dr. Sumeray held several positions of increasing responsibility within The Medicines Company, including Vice President and Business Unit Co-Leader, Vice President Medical Business Development, and Vice President Clinical Development and Head of Medical Science. Prior to that, Dr. Sumeray was worldwide Vice President of Clinical Development for the Ethicon Franchise of Johnson & Johnson.

Mary Weger 

Senior Vice President, Human Resources

Mary Weger was appointed Senior Vice President, Human Resources in December, 2011.  Mary brings over 30 years of Human Resource experience, eleven of which has been within the biopharmaceutical industry.  Prior to joining Aegerion, Mary was Senior Vice President, Global Clinical Development Strategy & Effectiveness at Celgene Corporation.  Prior to this appointment, she held the position of Senior Vice President, Global Human Resources at Celgene where she played an instrumental role in helping to build Celgene globally from a company with 150+ employees to a world-wide organization with revenue of over 4 billion and operations in over 30 countries.  Prior to Celgene, Mary held positions of increasing responsibility at Kraft Foods Nabisco.  She received her Masters certificate and Black Belt in Six Sigma in 2011 from Villanova University and also possesses a MA in Human Resource Management as well as having completed the Executive Human Resources program at Michigan University.  Mary currently serves on the Board of Family Promise, a non-profit organization addressing the needs of homeless families.